Infusion Therapy Safety: Clinical Standards and Best Practices

Infusion therapy is among the most complex and risk-laden clinical processes in healthcare. Every element of the infusion system — from the vascular access device to the administration set, from the pump to the needleless connector — represents a potential failure point. Medication errors involving IV medications are 2–3 times more likely to cause patient harm than errors involving oral medications, and IV-related adverse events represent a disproportionate share of preventable patient harm.

This guide covers the foundational safety standards for infusion therapy delivery: device and route selection for medications, filtration, flushing and locking protocols, vesicant management, high-alert medication safety, parenteral nutrition, and smart pump technology.

The Infusion System: Components and Risk Points

Every infusion reaches a patient through a connected system of components:

1. Vascular access device (VAD) — peripheral or central; defines the route and osmolarity tolerance
2. Extension set and add-on devices — increase connection points; each is a potential contamination and disconnection risk
3. Needleless connector (NLC) — access point for every catheter entry; requires disinfection at every use
4. Administration set — tubing from infusate container to patient; harbors microorganisms if not changed per protocol
5. Infusion pump — dose delivery; drug library compliance is critical for high-alert medications
6. Infusate container and medication — preparation errors, compounding errors, and compatibility issues

The current clinical standards address each component. The principle: minimize add-on devices to the minimum clinically required; every additional component adds infection risk, flow resistance, and potential failure.

Right Device for the Right Therapy

Device selection for infusion therapy must consider the osmolarity, pH, vesicant potential, volume requirements, and duration of the planned therapy.

Osmolarity Thresholds

Common medications exceeding peripheral thresholds:

• Concentrated potassium chloride (>40 mEq/L)
• Mannitol 20%
• Phenytoin
• Acyclovir at concentrations >7 mg/mL
• Vancomycin at concentrations >5 mg/mL (also highly irritant)
• TPN without lipids

pH Extremes

Medications with pH <5 or >9 cause chemical phlebitis at peripheral sites. Central access should be used for:

• Acyclovir (pH 11)
• Amphotericin B (pH 5–7 but highly irritant)
• Phenytoin (pH 12)
• Many chemotherapy agents

High-Alert Medications via IV Access

The Institute for Safe Medication Practices (ISMP) maintains a list of high-alert medications — drugs that bear a heightened risk of causing significant patient harm when used in error. Key IV high-alert medications include:

Smart pump drug libraries: ISMP recommends that all IV infusion pumps have dose error reduction software (DERS) with drug libraries covering high-alert medications. Hard limits (absolute maximum doses) should not be overrideable; soft limits (advisory alerts) should require documentation of clinical rationale to override. Annual drug library review is required.

Filtration Standards

In-line filtration during IV infusion removes particulate matter, microorganisms, and air. provides specific filtration guidance:

Medications that cannot be filtered through 0.2 micron filter:

• Lipid emulsions (particles are too large)
• Blood products (use 170–260 micron blood filter)
• Albumin (manufacturer guidance varies)
• Propofol (lipid-based; use 1.2 micron filter or in-line at pump)

Neonatal filtration: 0.2 micron filtration is particularly important in neonatal PN to reduce phlebitis risk in small, fragile veins and to filter potential particulate from compounded admixtures.

Filter change frequency: — change filters with the administration set per the set change schedule (maximum 96 hours for continuous infusion); more frequently for lipid-containing solutions (24 hours).

See Infusion Filtration Standards.

Flushing and Locking Protocols (SASH)

Consistent flushing and locking of vascular access devices prevents occlusion and reduces CLABSI risk by clearing the catheter of blood and infusate.

The SASH Protocol

SASH (for heparin-locked CVADs):

1. S — Saline flush: 10 mL NS before medication administration (confirms patency)
2. A — Administration: administer medication or infusion
3. S — Saline flush: 10 mL NS after medication (clears the lumen)
4. H — Heparin lock: per institutional protocol (typically 10 units/mL, 3–5 mL)

SASH-L (saline-only lock): Use saline 0.9% 10 mL before and after when heparin lock is not indicated (e.g., Groshong-type valved PICC, some protocols).

Flushing Technique

• Use pulsatile (push-pause) technique: alternating gentle pressure and release creates turbulent flow that is more effective at clearing the catheter lumen than steady continuous flush
• Use a 10 mL syringe minimum to generate safe intraluminal pressure (smaller syringes can exceed catheter pressure ratings — a 1 mL syringe generates up to 1,000+ psi; a 10 mL syringe generates approximately 25–40 psi, within catheter specifications)
• Positive pressure on final flush: Maintain forward pressure on the syringe plunger while withdrawing the syringe to prevent blood reflux into the catheter lumen

Heparin Lock Evidence

• Whether heparin or saline is superior for locking CVADs remains debated; meta-analyses show similar efficacy for both for patency maintenance in most CVAD types
• Saline lock is now recommended or preferred by many institutions (especially for short-term CVCs and PICCs) to reduce heparin exposure and HIT risk
• Heparin lock remains standard for implanted ports (per most manufacturer and institutional protocols) and for some tunneled catheter types
• the type and frequency of flushing/locking should be based on catheter manufacturer instructions, institutional protocol, and individual patient factors

Administration Set Change Frequency

Never leave infusion sets in place beyond their scheduled change time. Biofilm and microorganism colonization of administration set tubing increases with dwell time.

Vesicant Administration Safety

A vesicant is a substance that, when extravasated into tissue, can cause blistering, tissue necrosis, and permanent injury. Safe vesicant administration requires:

1. Central venous access for systemic vesicant infusions: Peripheral IV administration of vesicants is associated with dramatically higher extravasation risk due to catheter movement, PIV failure rates, and smaller vessel diameter
2. Pre-administration site assessment: Confirm brisk blood return and easy flushing before initiating vesicant infusion
3. Monitoring during infusion: Assess site every 1–4 hours during vesicant infusion; immediately upon any patient report of pain, burning, or swelling at the site
4. Extravasation response kit: Must be immediately accessible on any unit administering vesicants; contents include antidotes, documentation forms, and emergency contacts
5. Documentation: Vesicant administration site, blood return confirmation, assessment findings, and any adverse events must be documented at each assessment

Common vesicant drugs:

• Anthracyclines: doxorubicin, daunorubicin, idarubicin, epirubicin
• Vinca alkaloids: vincristine, vinblastine, vinorelbine
• DNA-alkylating agents: mechlorethamine, cisplatin (concentrated)
• Taxanes: paclitaxel, docetaxel
• Vasopressors: norepinephrine, dopamine, vasopressin (in peripheral IV)

See Vesicant Administration Safety and the Infiltration and Extravasation Guide.

Parenteral Nutrition (PN): Vascular Access Requirements

Parenteral nutrition is a complex, high-osmolarity admixture that requires specific vascular access considerations:

• Osmolarity requiring central access: PN solutions typically exceed 900 mOsm/L; standard-concentration TPN (20–25% dextrose + amino acids) must be administered via central access
• Peripheral parenteral nutrition (PPN): Lower-osmolarity PN formulations (<600–900 mOsm/L) can be administered peripherally; suitable only for short-term supplemental PN; high phlebitis rate
• Dedicated lumen: PN should have a dedicated catheter lumen when possible; incompatibility with many medications and blood products; risk of contamination with multi-access lumens
• Filtration: 1.2 micron filter for 3-in-1 (all-in-one with lipids); 0.2 micron filter for dextrose-amino acid only (no lipids)
• DEHP-free tubing: Required for neonatal PN (DEHP plasticizers leach from standard PVC tubing in the presence of lipids; DEHP is an endocrine disruptor; significant concern in preterm neonates)
• Light protection: Neonatal PN with multivitamins (vitamin A) requires light-protected tubing and bags; vitamin A degrades rapidly under phototherapy light

See Parenteral Nutrition Vascular Access Requirements.

Smart Pump Technology and DERS

Dose Error Reduction Software (DERS) in smart IV pumps is one of the most effective tools for preventing IV medication errors. Requirements:

• All high-alert medications should be covered in the drug library with clinical dose limits
• Hard limits should define the absolute upper boundary; hard limit overrides are not permitted
• Soft limits generate advisory alerts but can be overridden with documentation; soft limit compliance rates should be tracked (high override rates indicate need for library adjustment)
• Annual drug library review and update is required per Joint Commission
• DERS compliance rates (% of infusions programmed from library vs. free-form programming) should be monitored as a quality metric

Related Satellite Guides

• Infusion Filtration Standards: 0.2 vs 1.2 Micron
• Flushing and Locking: SASH Protocol and Evidence
• Vesicant Administration Safety
• High-Alert Medications via IV
• Parenteral Nutrition and Vascular Access

Related Policies

• Filtration Vascular Access
• Flushing and Locking Vascular Access Devices
• Administration Set Management
• Add-On Devices for Vascular Access Systems
• Needleless Connectors
• Hazardous Drug Management

References

2. ISMP. (2023). High-Alert Medications in Acute Care Settings. Institute for Safe Medication Practices.
3. Keränen U, et al. (2010). Improving adherence to filtration recommendations for peripheral parenteral nutrition. JPEN, 34(4):420–425.
4. Phillips LD & Gorski LA. (2014). Manual of I.V. Therapeutics (6th ed.). F.A. Davis.
5. ASHP. (2018). ASHP Guidelines on the Pharmacy and Therapeutics Committee and the Formulary System. Am J Health Syst Pharm, 75(5):282–293.